A pharmacokinetic profile of nizatidine in man.

John Callaghan, R. F. Bergstrom, A. Rubin, S. Chernish, R. Crabtree, M. P. Knadler, B. Obermeyer, W. W. Offen, D. W. Schneck, G. Aronoff

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In this report, the pharmacokinetic, pharmacodynamic, and hormonal effects of nizatidine are reviewed in healthy volunteers and in patients with renal or hepatic impairment. The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively. Within 16 h of dosing volunteers with nizatidine, more than 90% of the administered dose was recovered in urine as parent drug and metabolites; unchanged nizatidine accounted for 65 and 75% of the recovered substances, after oral and intravenous administration, respectively. Renal impairment decreased the elimination of nizatidine and dosage reductions are recommended for patients with creatinine clearance (Clcr) less than 50 ml/min/m2. Nizatidine suppressed gastric acid secretion produced by sham meals, protein meals, or pentagastrin; its antisecretory activity was dose and concentration dependent. Nizatidine was three times more potent than cimetidine. Nizatidine, after oral or iv administration, did not alter hormone concentrations in plasma.

Original languageEnglish (US)
Pages (from-to)9-17
Number of pages9
JournalScandinavian Journal of Gastroenterology, Supplement
Volume136
StatePublished - 1987

Fingerprint

Nizatidine
Pharmacokinetics
Meals
Kidney
Pentagastrin
Gastric Acid
Cimetidine
Intravenous Administration
Biological Availability
Oral Administration
Half-Life
Volunteers
Creatinine
Healthy Volunteers
Parents
Urine

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Callaghan, J., Bergstrom, R. F., Rubin, A., Chernish, S., Crabtree, R., Knadler, M. P., ... Aronoff, G. (1987). A pharmacokinetic profile of nizatidine in man. Scandinavian Journal of Gastroenterology, Supplement, 136, 9-17.

A pharmacokinetic profile of nizatidine in man. / Callaghan, John; Bergstrom, R. F.; Rubin, A.; Chernish, S.; Crabtree, R.; Knadler, M. P.; Obermeyer, B.; Offen, W. W.; Schneck, D. W.; Aronoff, G.

In: Scandinavian Journal of Gastroenterology, Supplement, Vol. 136, 1987, p. 9-17.

Research output: Contribution to journalArticle

Callaghan, J, Bergstrom, RF, Rubin, A, Chernish, S, Crabtree, R, Knadler, MP, Obermeyer, B, Offen, WW, Schneck, DW & Aronoff, G 1987, 'A pharmacokinetic profile of nizatidine in man.', Scandinavian Journal of Gastroenterology, Supplement, vol. 136, pp. 9-17.
Callaghan J, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP et al. A pharmacokinetic profile of nizatidine in man. Scandinavian Journal of Gastroenterology, Supplement. 1987;136:9-17.
Callaghan, John ; Bergstrom, R. F. ; Rubin, A. ; Chernish, S. ; Crabtree, R. ; Knadler, M. P. ; Obermeyer, B. ; Offen, W. W. ; Schneck, D. W. ; Aronoff, G. / A pharmacokinetic profile of nizatidine in man. In: Scandinavian Journal of Gastroenterology, Supplement. 1987 ; Vol. 136. pp. 9-17.
@article{dd9a806109de45fe94ec073f1efa6bbe,
title = "A pharmacokinetic profile of nizatidine in man.",
abstract = "In this report, the pharmacokinetic, pharmacodynamic, and hormonal effects of nizatidine are reviewed in healthy volunteers and in patients with renal or hepatic impairment. The absolute oral bioavailability of nizatidine exceeded 90{\%}; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively. Within 16 h of dosing volunteers with nizatidine, more than 90{\%} of the administered dose was recovered in urine as parent drug and metabolites; unchanged nizatidine accounted for 65 and 75{\%} of the recovered substances, after oral and intravenous administration, respectively. Renal impairment decreased the elimination of nizatidine and dosage reductions are recommended for patients with creatinine clearance (Clcr) less than 50 ml/min/m2. Nizatidine suppressed gastric acid secretion produced by sham meals, protein meals, or pentagastrin; its antisecretory activity was dose and concentration dependent. Nizatidine was three times more potent than cimetidine. Nizatidine, after oral or iv administration, did not alter hormone concentrations in plasma.",
author = "John Callaghan and Bergstrom, {R. F.} and A. Rubin and S. Chernish and R. Crabtree and Knadler, {M. P.} and B. Obermeyer and Offen, {W. W.} and Schneck, {D. W.} and G. Aronoff",
year = "1987",
language = "English (US)",
volume = "136",
pages = "9--17",
journal = "Scandinavian Journal of Gastroenterology, Supplement",
issn = "0085-5928",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - A pharmacokinetic profile of nizatidine in man.

AU - Callaghan, John

AU - Bergstrom, R. F.

AU - Rubin, A.

AU - Chernish, S.

AU - Crabtree, R.

AU - Knadler, M. P.

AU - Obermeyer, B.

AU - Offen, W. W.

AU - Schneck, D. W.

AU - Aronoff, G.

PY - 1987

Y1 - 1987

N2 - In this report, the pharmacokinetic, pharmacodynamic, and hormonal effects of nizatidine are reviewed in healthy volunteers and in patients with renal or hepatic impairment. The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively. Within 16 h of dosing volunteers with nizatidine, more than 90% of the administered dose was recovered in urine as parent drug and metabolites; unchanged nizatidine accounted for 65 and 75% of the recovered substances, after oral and intravenous administration, respectively. Renal impairment decreased the elimination of nizatidine and dosage reductions are recommended for patients with creatinine clearance (Clcr) less than 50 ml/min/m2. Nizatidine suppressed gastric acid secretion produced by sham meals, protein meals, or pentagastrin; its antisecretory activity was dose and concentration dependent. Nizatidine was three times more potent than cimetidine. Nizatidine, after oral or iv administration, did not alter hormone concentrations in plasma.

AB - In this report, the pharmacokinetic, pharmacodynamic, and hormonal effects of nizatidine are reviewed in healthy volunteers and in patients with renal or hepatic impairment. The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively. Within 16 h of dosing volunteers with nizatidine, more than 90% of the administered dose was recovered in urine as parent drug and metabolites; unchanged nizatidine accounted for 65 and 75% of the recovered substances, after oral and intravenous administration, respectively. Renal impairment decreased the elimination of nizatidine and dosage reductions are recommended for patients with creatinine clearance (Clcr) less than 50 ml/min/m2. Nizatidine suppressed gastric acid secretion produced by sham meals, protein meals, or pentagastrin; its antisecretory activity was dose and concentration dependent. Nizatidine was three times more potent than cimetidine. Nizatidine, after oral or iv administration, did not alter hormone concentrations in plasma.

UR - http://www.scopus.com/inward/record.url?scp=0023503483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023503483&partnerID=8YFLogxK

M3 - Article

C2 - 2892261

AN - SCOPUS:0023503483

VL - 136

SP - 9

EP - 17

JO - Scandinavian Journal of Gastroenterology, Supplement

JF - Scandinavian Journal of Gastroenterology, Supplement

SN - 0085-5928

ER -